Skip to main content


Fig. 1 | Thrombosis Journal

Fig. 1

From: Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

Fig. 1

Study design at loading dose. Forty patients who were scheduled for percutaneous coronary intervention (PCI) under treatment with aspirin were randomized at admission to treatment of either a 20-mg loading dose (LD) of prasugrel or a 300-mg LD of clopidogrel. Platelet function analyses were performed at five time points (baseline, and 0.5, 3, 6, and 20 h) after the LD. Active metabolite concentrations were measured at 0.5 and 3 h after the LD

Back to article page